Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
AENEAS2
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
- NCT04923906 ↗
- Active, not recruiting
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on AENEAS2 (aumolertinib in Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AENEAS2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Efficacy and Safety of Aumolertinib with or Without Chemotherapy As First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing Epidermal Growth Factor Receptor Mutations: a Randomized, Controlled, Open-label, Phase 3 and Multicenter Clinical Study
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Aumolertinib; Placebo Aumolertinib
- Arms
- Aumolertinib and platinum-based chemotherapy · Experimental
- Aumolertinib · Active comparator
- Enrollment
- 624 (estimated)
- Primary outcomes
- PFS (Progression Free Survival) assessed by IRC (Independent Review Committee)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Start
- Aug 11, 2021
- Primary completion
- Jun 18, 2024
- Results posted
- No
- Registry record
- NCT04923906 · updated Nov 25, 2024
Publications
linked from the registry- Li Z, Hu J, Chen J, Yu Y, Meng X, Dong X, Hu Y, Ji Y, Liu H, Wang W, Ning F, Zhang Z, Liu C, Zhang Z, Wang Q, Zheng W, Wang H, Qu X, Chen Z, Fan S, Zhang X, Lu S. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Jul;27(7):785-794. doi: 10.1016/S1470-2045(26)00090-2. Epub 2026 Jun 15. PubMed 42296979